Welcome to our dedicated page for Oragenics SEC filings (Ticker: OGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech is hard enough without digging through dense disclosures. Oragenics’ SEC documents run hundreds of pages, mixing trial data, FDA milestones, and detailed cash-burn tables that can overwhelm even seasoned analysts. If you have ever wondered, “How do I locate Oragenics insider trading Form 4 transactions or make sense of its R&D footnotes?”, you are not alone.
Stock Titan’s platform turns that problem into a two-minute task. Our AI reads every newly posted filing on EDGAR, from a Oragenics quarterly earnings report 10-Q filing to an unexpected 8-K, and produces clear summaries with plain-language call-outs. Need real-time alerts for Oragenics Form 4 insider transactions real-time? They appear on your dashboard seconds after the company submits them. Prefer narrative context? The “Explain” tab delivers Oragenics SEC filings explained simply, spotlighting clinical-trial spend, debt covenants, and dilution clauses so you can act quickly.
Beyond headline numbers, our coverage links filing types to what matters for this pipeline-focused company:
- 10-K simplified: See how much runway remains for the synthetic neurosteroid program with a single click – no scrolling required (Oragenics annual report 10-K simplified).
- 8-K material events explained: Catch partnership announcements or FDA feedback moments after they post (Oragenics 8-K material events explained).
- Form 4 oversight: Monitor Oragenics executive stock transactions Form 4 and spot insider confidence shifts.
- Proxy insights: Review Oragenics proxy statement executive compensation without wading through legalese.
Whether you are comparing quarter-over-quarter burn rates with Oragenics earnings report filing analysis or simply understanding Oragenics SEC documents with AI, Stock Titan delivers the data, context, and speed professionals need.
Overview: Morgan Stanley Finance LLC ("MSFL") is marketing $1,000-denominated Buffered Jump Securities with an Auto-Callable feature that mature on August 5, 2030 and are fully and unconditionally guaranteed by Morgan Stanley. The notes are linked to the S&P U.S. Equity Momentum 40% VT 4% Decrement Index and do not pay periodic interest.
Auto-call mechanics: Beginning with the first determination date on August 3, 2026, the notes will be automatically redeemed if the Underlier closes at or above 90 % of its initial level. Early-redemption payments escalate from roughly $1,152.50 (≈ 15.25 % return) on the first call date to about $1,798.96 (≈ 79.9 % return) on the last call date prior to maturity. Once called, no further payments are made.
Principal repayment scenarios at maturity:
- If the notes have not been called and the Underlier is ≥ 90 % of its initial level, investors receive $1,762.50–$1,812.50 (≈ 76 %–81 % upside).
- If the Underlier is < 90 % but ≥ 80 % (the 20 % buffer), investors receive only the $1,000 principal.
- If the Underlier is < 80 %, repayment equals $1,000 × (final level / initial level + 0.20), subject to a minimum of 20 % of principal, exposing investors to up to 80 % loss.
Valuation & distribution: The estimated value on the July 31, 2025 pricing date is approximately $934.20—about 6.6 % below the $1,000 issue price—reflecting structuring and hedging costs. The notes will be sold only to fee-based advisory accounts; MS&Co. receives no traditional sales commission but may pay dealers a structuring fee up to $6.25 per note.
Key risks: (i) principal at risk and limited upside participation; (ii) unsecured creditor exposure to Morgan Stanley; (iii) no exchange listing; (iv) secondary market prices expected to be below issue price; (v) reinvestment risk if auto-called early.
Oragenics, Inc. (NYSE American: OGEN) has filed a Form S-1 to raise capital through a best-efforts offering of up to 800,000 shares of Series H Non-Voting Convertible Preferred Stock and an equal number of accompanying five-year warrants. Each Preferred share and warrant unit will be sold at a fixed combined price of $25.00, providing gross proceeds of up to $20 million before fees and expenses if the offering is fully subscribed. Dawson James Securities will act as placement agent for a cash fee equal to 7.0 % of gross proceeds.
Key structural terms
- Conversion mechanics: The Conversion Price will be set at pricing, likely tied to the prevailing common-share price and may include a discount. Illustrative examples show conversion ratios of 6.94 common shares per Preferred share at a $3.60 Conversion Price and 10 common shares per Preferred share at a $2.50 Conversion Price.
- Anti-dilution feature: A full-ratchet provision lowers the Conversion Price of any unconverted Preferred shares to match the price of future equity issuances, with no stated floor. This can materially increase the number of common shares issuable and intensify dilution risk.
- Warrants: Immediately exercisable at $25.00 per Preferred share; expire five years after issuance.
- Maximum share issuance: The prospectus registers up to 17,095,822 common shares—reflecting the company’s good-faith estimate of shares that could be issued upon conversion of all Preferred shares (including those underlying warrants) plus stock-settled dividends.
- Listing & liquidity: Neither the Preferred shares nor the warrants will be listed on any exchange, and the company does not expect an active secondary market to develop.
Capital-markets context
- The company completed a 1-for-30 reverse stock split on 3 June 2025, which reduced outstanding common shares and increased the per-share price.
- On 18 June 2025 the common stock closed at $4.37. This reference price will influence the eventual Conversion Price.
- Oragenics has received NYSE American deficiency letters for failing the stockholders’ equity tests in Sections 1003(a)(i)–(iii). A compliance plan was accepted on 18 June 2024, giving the company until 18 October 2025 to regain compliance or face delisting procedures.
Risk and proceeds considerations
- No minimum raise & no escrow: Investors may receive no refund if the company raises insufficient funds to execute its business plan.
- Dilution & share availability: Because the anti-dilution feature has no floor, the total shares required to satisfy conversions is indeterminable. The company may be forced to seek shareholder approval to increase authorized shares, which is time-consuming and uncertain.
- Arbitrary pricing: Management—not the market—set the $25.00 unit price and warrant exercise price, which may not reflect intrinsic value.
The offering will terminate no later than 31 July 2025. Proceeds, if any, are expected to provide general working capital and support ongoing efforts to regain exchange compliance, although specific use-of-proceeds details are not disclosed in the excerpt.
Key takeaways from Oragenics Inc. (OGEN) Form 4:
- Reporting person: Odyssey Health, Inc., designated as a 10% owner.
- Two open-market sales of common stock were disclosed.
- 17 Jun 2025: 2,000 shares sold at $4.46.
- 18 Jun 2025: 5,044 shares sold at $4.26.
After completing these transactions, Odyssey Health reports 0 shares of Oragenics common stock remaining, indicating a full divestiture of its previously reportable stake. All transactions were coded “S” (sale) and were executed directly; no derivative securities or additional transactions were reported.
FAQ
What is the current stock price of Oragenics (OGEN)?
What is the market cap of Oragenics (OGEN)?
What is the core focus of Oragenics?
How does Oragenics develop its products?
What makes Oragenics' approach to drug delivery unique?
Which therapeutic areas does Oragenics target?
What is the significance of the intranasal casting studies?
How does Oragenics maintain regulatory standards in its research?
What are the competitive advantages of Oragenics in the biopharmaceutical market?
How does Oragenics communicate its scientific research to stakeholders?
